The association between osteoporosis and oral bone loss

Journal of Periodontology

Volumn 76, Issue 11 SUPPL., 2005, Pages 2125-2132

  Jeffcoat, Marjorie ^a  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Bone; Osteopenia; Osteoporosis; Therapy

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VITAMIN D;

ALVEOLAR BONE; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; BONE NECROSIS; BONE RADIOGRAPHY; BREAST CANCER; CALCIUM INTAKE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG RECEPTOR BINDING; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY DIAGNOSIS; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LONGITUDINAL STUDY; MANDIBLE; META ANALYSIS; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OSTEOSARCOMA; PERIODONTAL DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PROSTHESIS FAILURE; RADIODENSITOMETRY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SKULL RADIOGRAPHY; SPINE FRACTURE; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

AGE FACTORS; ALVEOLAR BONE LOSS; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DENSITOMETRY, X-RAY; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MANDIBULAR DISEASES; OSTEOPOROSIS; RADIOGRAPHY, DENTAL, DIGITAL; RISK FACTORS; VITAMIN D;

EID: 28644434590     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2005.76.11-S.2125     Document Type: Article

References (59)

1. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group. World Health Organ Techn Rep Ser 1994;843:1-129.
2. U.S. Department of Health and Human Services. Bone health and osteoporosis: A report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General; 2004.
3. Vico L, Prallet B, Chappard D, Pallot-Prades B, Pupier R, Alexandre C. Contributions of chronological age, age at menarche and menopause and of anthropometric parameters to axial and peripheral bone densities. Osteoporos Int 1992;2:153-158.
4. Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002;23:279-302.
5. Holbrook TL, Barrett-Connor E, Wingard DL. Dietary calcium and risk of hip fracture: 14-year prospective population study. Lancet 1988;ii(Nov):1046-1049.
6. Bonaiuti D, Shea B, Iovine R, et al., Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2002;(3): CD000333.
7. Cumming RG, Thomas M, Szonyi G, et al. Home visits by an occupational therapist for assessment and modification of environmental hazards: A randomized trial of falls prevention. J Am Geriatr Soc 1999;47: 1397-1402.
8. Baron JA, Farahmand BY, Weiderpass E, et al. Cigarette smoking, alcohol consumption, and risk of hip fracture in women. Arch Intern Med 2001;161:983-988.
9. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: Recognition of a major effect. Br Med J 1997;315:841-846.
10. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis. Osteoporos Int 2002;13:777-787.
11. Melton LJ. Epidemiology of fractures. In: Riggs BL, Melton LJ, eds. Osteoporosis: Etiology, Diagnosis and Management. New York: Raven Press; 1988:133-154.
12. Lindsay R. Estrogens, bone mass and osteoporotic fracture. Am J Med 1991;91(Suppl. 5B):10S-13S.
13. Kellie SE, Brody JA. Sex-specific and race-specific hip fracture rates. Am J Public Health 1990;80:326-328.
14. Villa ML, Nelson L. Race, ethnicity and osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press; 1996:435-447.
15. Wahner HW, Fogelman I. The evaluation of osteoporosis: Dual energy x-ray absorptiometry in clinical practice. London: Martin Dunitz; 1994.
16. Klemetti E, Vainio P, Lassila V, Alhava E. Trabecular bone mineral density of mandible and alveolar height in postmenopausal women. Scand J Dent Res 1993; 101:166-170.
17. Klemetti E, Kolmakov S, Kröger H. Pantomography in the assessment of the osteoporosis risk group. Scand J Dent Res 1994;102:68-72.
18. Taguchi A, Tanimoto K, Suei Y, Otani K, Wada T. Oral signs as indicators of possible osteoporosis in elderly women. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:612-616.
19. Jeffcoat MK, Reddy MS. Alveolar bone loss and osteoporosis: Evidence for a common mode of therapy using the bisphosphonate alendronate. In: Davidovitch Z, ed. The Biologic Mechanism of Tooth Resorption and Replacement by Implants. Boston: Harvard Society for the Advancement of Orthodontics; 1996:365-373.
20. Jeffcoat MK, Reddy MS, Magnusson I, et al. Efficacy of quantitative digital subtraction radiography using radiographs exposed in a multicenter trial. J Periodontal Res 1996;31:157-160.
21. Buckland-Wright JC, Lynch JA, Rymer J, Fogelman I. Fractal signature analysis of macroradiographs measures trabecular organization in lumbar vertebrae of postmenopausal women. Calcif Tissue Int 1994;54: 106-112.
22. Caligiuri P, Giger ML, Favus M. Multifractal radiographic analysis of osteoporosis. Med Phys 1994;21: 503-508.
23. Ruttimann UE, Webber RL, Hazelrig JB. Fractal dimension from radiographs of peridental alveolar bone. A possible diagnostic indicator of osteoporosis. Oral Surg Oral Med Oral Pathol 1992;74:98-110.
24. Southard KA, Southard TE. Comparison of digitized radiographic alveolar features between 20- and 70- year-old women. A preliminary study. Oral Surg Oral Med Oral Pathol 1992;74:111-117.
25. Jonasson G, Bankvall G, Kiliaridis S. Estimation of skeletal bone mineral density by means of the trabecular pattern of the alveolar bone, its interdental thickness, and the bone mass of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:346-352.
26. Kribbs PJ, Smith DE, Chesnut CH. Oral findings in osteoporosis. Part II: Relationship between residual ridge and alveolar bone resorption and generalized skeletal osteopenia. J Prosthet Dent 1983;50:719-724.
27. Kribbs PJ, Chesnut CH, Ott SM, Kilcoyne RF. Relationships between mandibular and skeletal bone in an osteoporotic population. J Prosthet Dent 1989;62: 703-707.
28. Kribbs PJ. Comparison of mandibular bone in normal and osteoporotic women. J Prosthet Dent 1990;63: 218-222.
29. Jacobs R, Ghyselen J, Koninckx P, van Steenberghe D. Long-term bone mass evaluation of mandible and lumbar spine in a group of women receiving hormone replacement therapy. Eur J Oral Sci 1996; 104:10-16.
30. von Wowern N, Klausen B, Kollerup G. Osteoporosis: A risk factor in periodontal disease. J Periodontol 1994;65:1134-1138.
31. Wactawski-Wende J, Grossi SG, Trevisan M, et al. The role of osteopenia in oral bone loss and periodontal disease. J Periodontol 1996;67:1076-1084.
32. Streckfus CF, Johnson RB, Nick T, Tsao A, Tucci M. Comparison of alveolar bone loss, alveolar bone density and second metacarpal bone density, salivary and gingival crevicular fluid interleukin-6 concentrations in healthy premenopausal and postmenopausal women on estrogen therapy. J Gerontol A Biol Sci Med Sci 1997;52:M343-M351.
33. Jeffcoat MK, Lewis CE, Reddy MS, Wang C-Y, Redford M. Post-menopausal bone loss and its relationship to oral bone loss. Periodontol 2000 2000; 23:94-102.
34. Tezal M, Wactawski-Wende J, Grossi SG, Ho AW, Dunford R, Genco RJ. The relationship between bone mineral density and periodontitis in postmenopausal women. J Periodontol 2000;71:1492-1498.
35. Hildebolt CF, Pilgram TK, Yokoyama-Crothers N, et al. The pattern of alveolar crest height change in healthy postmenopausal women after 3 years of hormone/ estrogen replacement therapy. J Periodontol 2002;73: 1279-1284.
36. Mohammad AR, Hooper DA, Vermilyea SG, Mariotti A, Preshaw PM. An investigation of the relationship between systemic bone density and clinical periodontal status in post-menopausal Asian-American women. Int Dent J 2003;53:121-125.
37. Geurs NC, Lewis CE, Jeffcoat MK. Osteoporosis and periodontal disease progression. Periodontol 2000 2003;32:105-110.
38. Yoshihara A, Seida Y, Hanada N, Miyazaki H. A longitudinal study of the relationship between periodontal disease and bone mineral density in community-dwelling older adults. J Clin Periodontol 2004;31: 680-684.
39. Elders PJM, Habets LLMH, Netelenbos JC, van der Linden LWJ, van der Stelt PF. The relation between periodontitis and systemic bone mass in women between 46 and 55 years of age. J Clin Periodontol 1992;19:492-496.
40. Weyant RJ, Pearlstein ME, Churak AP, Forrest K, Famili P, Cauley JA. The association between osteopenia and periodontal attachment loss in older women. J Periodontol 1999;70:982-991.
41. Institute of Medicine. Dietary Reference Intakes for Calcium, Vitamin D and Fluoride. Washington, DC: National Academy Press; 1997.
42. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-333.
43. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA 2003;290:1729-1738.
44. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative Randomized Controlled Trial. JAMA 2004;291: 1701-1712.
45. National Institutes of Health. PH Index. Available at: http://www.nih.gov/PHindex.htm. Accessed April 1, 2005.
46. Harada S-I, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003;423:349-355.
47. Papapoulos SE. Bisphosphonates. Pharmacology and use in the treatment of osteoporosis. In: Marcus RE, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press; 1996:1209-1234.
48. Cummings SR, Black DM, Thompson DE. Effect of alendronate on the risk of fracture in women with low bone density but without vertebral fractures. Results from the fracture intervention trial. JAMA 1998;280: 2077-2082.
49. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-4124.
50. Bone HG, Hosking D, Devogelaer J-P, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199.
51. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 1999;282: 1344-1352.
52. Rocha ML, Malacara JM, Sánchez-Marin FJ, Vazquez de la Torre CJ, Fajardo ME. Effect of alendronate on periodontal disease in postmenopausal women: A randomized placebo-controlled trial. J Periodontol 2004;75:1579-1585.
53. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study. Am J Med 2000;109:267-276.
54. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.
55. Cosman F, Lindsay R. Selective estrogen receptor modulators: Clinical spectrum. Endocr Rev 1999;20: 418-434.
56. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebal fracture risk reduction in post-menopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-3617.
57. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.
58. Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88:5212-5220.
59. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)]are dependent on the duration of treatment and dose. Toxicol Pathol 2004;32:426-438.